World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
80
Citations
27840
World Ranking
1609
National Ranking
803

Adrian B. McDermott publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Adrian B. McDermott sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 287 publications — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Adrian B. McDermott D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Adrian B. McDermott sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 80 D-Index — 68th percentile

68% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Adrian B. McDermott is affiliated with the National Institute of Allergy and Infectious Diseases in the United States. Their research primarily focuses on medicine and immunology and microbiology, with particular attention to infectious diseases, immunology, epidemiology, virology, and radiology-related imaging disciplines.

Their main topics of work include SARS-CoV-2 and COVID-19 research, HIV research and treatment, influenza virus research studies, immunotherapy and immune responses, monoclonal and polyclonal antibodies research, HIV/AIDS drug development and treatment, and animal virus infections studies.

McDermott's research output is reflected in frequent publications across a variety of scientific journals. The most common venues where their work appears include bioRxiv (Cold Spring Harbor Laboratory), Science Translational Medicine, the New England Journal of Medicine, UNC Libraries, and Science.

They have collaborated extensively with several other researchers. Frequent co-authors include John R. Mascola, Richard A. Koup, Sandeep Narpala, Sarah O'Connell, and Sarah F. Andrews.

Among the recent papers associated with this researcher are:

  • An mRNA Vaccine against SARS-CoV-2 - Preliminary Report, 2020, New England Journal of Medicine
  • Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults, 2020, New England Journal of Medicine
  • Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial, 2022, Science
  • Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates, 2020, New England Journal of Medicine
  • Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination, 2020, New England Journal of Medicine

Best Publications

  • An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

    Lisa A. Jackson;Evan J. Anderson;Nadine G. Rouphael;Paul C. Roberts

  • Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.

    Evan J. Anderson;Nadine G. Rouphael;Alicia T. Widge;Lisa A. Jackson

  • Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.

    Kizzmekia S Corbett;Barbara Flynn;Kathryn E Foulds;Joseph R Francica

  • Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.

    Peter B Gilbert;Peter B Gilbert;David C Montefiori;Adrian B McDermott;Youyi Fong

  • Homologous and Heterologous Covid-19 Booster Vaccinations

    Unknown

  • Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

    Alicia T. Widge;Nadine G. Rouphael;Lisa A. Jackson;Evan J. Anderson

  • Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

    Nicole Doria-Rose;Mehul S. Suthar;Mat Makowski;Sarah O’Connell

  • Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.

    Pegu, Amarendra, O’Connell, Sarah E.;Stephen D. Schmidt;O’Dell, Sijy, Talana, Chloe A.

  • Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

    Rebecca M. Lynch;Eli Boritz;Emily E. Coates;Adam DeZure

  • Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env

    Young Do Kwon;Marie Pancera;Priyamvada Acharya;Ivelin S. Georgiev

  • Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site

    Masaru Kanekiyo;Wei Bu;M. Gordon Joyce;Geng Meng

  • Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses

    M. Gordon Joyce;Adam K. Wheatley;Paul V. Thomas;Gwo-Yu Chuang

  • mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

    Unknown

  • Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag

    Danilo R. Casimiro;Fubao Wang;William A. Schleif;Xiaoping Liang

  • Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

    Masaru Kanekiyo;M Gordon Joyce;M Gordon Joyce;Rebecca A Gillespie;John R Gallagher

  • HIV vaccine design: insights from live attenuated SIV vaccines

    Wayne C Koff;Philip R Johnson;David I Watkins;Dennis R Burton

  • Vaccination induces HIV broadly neutralizing antibody precursors in humans

    Unknown

  • Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.

    K. Xu;P. Acharya;R. Kong;C. Cheng

  • A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite

    Neville K. Kisalu;Azza H. Idris;Connor Weidle;Yevel Flores-Garcia

  • Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239

    Nancy A. Wilson;Jason Reed;Gnankang S. Napoe;Shari Piaskowski

  • Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.

    J. E. Ledgerwood;E. E. Coates;G. Yamshchikov;J. G. Saunders

  • Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.

    Kizzmekia S. Corbett;Martha C. Nason;Britta Flach;Matthew Gagne

  • Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses.

    David H. O'Connor;Bianca R. Mothe;Jason T. Weinfurter;Sarah Fuenger

  • Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1

    Kai Xu;Priyamvada Acharya;Rui Kong;Cheng Cheng

Frequent Co-Authors

John R. Mascola
John R. Mascola ModeX Therapeutics
Barney S. Graham
Barney S. Graham Morehouse School of Medicine
Julie E. Ledgerwood
Julie E. Ledgerwood National Institute of Allergy and Infectious Diseases
Peter D. Kwong
Peter D. Kwong Columbia University Medical Center
Richard A. Koup
Richard A. Koup National Institute of Allergy and Infectious Diseases
Adam K. Wheatley
Adam K. Wheatley University of Melbourne
Robert T. Bailer
Robert T. Bailer National Institute of Allergy and Infectious Diseases
Daniel C. Douek
Daniel C. Douek National Institute of Allergy and Infectious Diseases
M. Gordon Joyce
M. Gordon Joyce Henry M. Jackson Foundation
Gwo-Yu Chuang
Gwo-Yu Chuang Moderna Therapeutics (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can open diverse career pathways. Many professionals opt to enhance their qualifications by enrolling in specialized nursing programs. For example, transitioning from family nurse practitioner (FNP) roles to acute care nurse practitioner (ACNP) positions requires dedicated training, and you can explore quality acnp programs designed to support this shift.

Accelerated options are also available for those looking to fast-track their nursing careers. The growing availability of accelerated np programs online allows students to complete their degrees more efficiently without sacrificing educational quality.

For individuals without a nursing background, enrolling in online RN programs for non nurses in Florida offers an excellent pathway to enter the healthcare field, providing foundational knowledge applicable in immunological research and clinical practice.

Understanding financial prospects is crucial when choosing a career path. Those pursuing a Doctor of Nursing Practice (DNP) can review the dnp salary by specialty to evaluate potential earnings and make informed decisions about specialization areas.

Best Scientists Citing Adrian B. McDermott

Trending Scientists

Recently Published Articles